Search research articles
Contact Us
Filters
Showing results (61-70 of 109) with videos related to
Page
of 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 13, 2018
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial
M Ignatiadis, S Litière, F Rothe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
B Gerber, S Loibl, H Eidtmann, et al.
Breast (Edinburgh, Scotland)
|
July 22, 2017
Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study
Elisabeth Trapp, J Steidl, B Rack, et al.
Geburtshilfe Und Frauenheilkunde
|
April 29, 2014
Full Field Digital Mammography (FFDM) versus CMOS Technology, Specimen Radiography System (SRS) and Tomosynthesis (DBT) - Which System Can Optimise Surgical Therapy?
R Schulz-Wendtland, G Dilbat, M Bani, et al.
Geburtshilfe Und Frauenheilkunde
|
April 29, 2014
Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis
P A Fasching, A B Ekici, D L Wachter, et al.
ESMO Open
|
November 28, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
V Müller, M Banys-Paluchowski, T W P Friedl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 26, 2013
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
G von Minckwitz, M Rezai, P A Fasching, et al.
Geburtshilfe Und Frauenheilkunde
|
September 26, 2014
Breast Cancer Risk - Genes, Environment and Clinics
P A Fasching, A B Ekici, B R Adamietz, et al.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
ESMO Open
|
May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study
T Decker, C Brucker, A Engel, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 109) with videos related to
Sort By:
Page
of 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 13, 2018
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial
M Ignatiadis, S Litière, F Rothe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
B Gerber, S Loibl, H Eidtmann, et al.
Breast (Edinburgh, Scotland)
|
July 22, 2017
Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study
Elisabeth Trapp, J Steidl, B Rack, et al.
Geburtshilfe Und Frauenheilkunde
|
April 29, 2014
Full Field Digital Mammography (FFDM) versus CMOS Technology, Specimen Radiography System (SRS) and Tomosynthesis (DBT) - Which System Can Optimise Surgical Therapy?
R Schulz-Wendtland, G Dilbat, M Bani, et al.
Geburtshilfe Und Frauenheilkunde
|
April 29, 2014
Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis
P A Fasching, A B Ekici, D L Wachter, et al.
ESMO Open
|
November 28, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
V Müller, M Banys-Paluchowski, T W P Friedl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 26, 2013
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
G von Minckwitz, M Rezai, P A Fasching, et al.
Geburtshilfe Und Frauenheilkunde
|
September 26, 2014
Breast Cancer Risk - Genes, Environment and Clinics
P A Fasching, A B Ekici, B R Adamietz, et al.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
ESMO Open
|
May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study
T Decker, C Brucker, A Engel, et al.
Page
of 11